NCT06329882 Doxycycline in Type II Diabetes
| NCT ID | NCT06329882 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Mostafa Bahaa |
| Condition | Diabetes Mellitus, Type 2 |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-03-30 |
| Primary Completion | 2026-03-20 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, weight loss, and cardio-metabolic complications. T2DM develops due to the progression of insulin resistance (IR), impairment of insulin insensitivity, and failure of the pancreatic β-cells to release sufficient amount of insulin in response to glucose burden
Eligibility Criteria
Inclusion Criteria: * Male or female sex more than 40 years old Newly diagnosed type II diabetes. HbA1c more than 6.5 Exclusion Criteria: * Patient with chronic kidney disease, hepatic disorders, mental and psychiatric disorders, pregnancy, and lactation
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.